D-0570-2023 Class III Terminated

Recalled by The Harvard Drug Group — La Vergne, TN

FDA drug recall D-0570-2023 was initiated by The Harvard Drug Group on Apr 24, 2023 and is designated Class III. Reason for recall: Product mixup: one foreign tablet found in product. The recall status is terminated (terminated Apr 30, 2024). Affected quantity: 3984 cartons.

Recall details

Product Type
Drugs
Report Date
May 17, 2023
Initiation Date
Apr 24, 2023
Termination Date
Apr 30, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3984 cartons

Product description

Gabapentin Tablets, USP 600 mg, packaged in Cartons of 100 tablets (10 tablets per blister pack x 10), Rx Only, Distributed by: Aurobindo Pharma USA, Inc. East Windsor, NJ 08520 Distributed by: Major Pharmaceuticals 17177 N Laurel Park Dr., Suite 233 Livonia, MI 48152 USA, NDC 0904-6823-61

Reason for recall

Product mixup: one foreign tablet found in product.

Distribution pattern

USA Nationwide

Code information

Lot: T04468, Exp 10/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0570-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0570-2023. Report a data issue: hello@regdatalab.com.